According to a pharmacoeconomic analysis titled "Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks with Heart Failure" published today in Circulation: Journal of the American Heart Association, BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) is a cost-effective way to treat heart failure in self-identified black patients.
Through Reduced Hospitalization, Cost of Care in Black Patients; Analysis Published Today in Circulation: Journal of the American Heart Association
Wednesday, December 14, 2005—According to a pharmacoeconomic analysis titled "Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks with Heart Failure" published today in Circulation: Journal of the American Heart Association, BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) is a cost-effective way to treat heart failure in self-identified black patients. Study results indicate that treatment with BiDil in the African American Heart Failure Trial (A-HeFT) reduced heart failure-related and all healthcare resource use and costs, due primarily to substantial reductions in both number and length of heart failure-related hospitalizations.
NitroMed's (NASDAQ: NTMD) BiDil was approved in June 2005 by the U.S. Food and Drug Administration (FDA) and is indicated to improve survival, prolong time to hospitalization for heart failure and improve patient-reported functional status in self-identified black patients when used as an adjunct to current standard therapy.
